I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Brian has extensive experience in research, writing and editing in the medical area. He is an author on multiple scientific papers. He greatly enjoys designing and running clinical translational projects. Brian graduated magna cum laude with a B.S. in Physiology and Neurobiology from the University of Maryland. He is currently an MD/PhD student in Integrative Biology and Disease at the University of Southern California, performing exercise physiology research. As part of his achievements, he is first author on 2 oral presentations at national conferences, Experimental Biology and American College of Sports Medicine, and published over 5 poster presentations including USC/Caltech and American Physician Scientist Association along with 3 publications with more in preparation. Brian greatly enjoys writing on all things and sharing his viewpoints on the latest tech and science.
Small business owner and investor. I've been involved with investing dating back to when I opened my first account at Olde Discount Brokers back in 1998 before it was purchased by H&R Block. My area of focus and ability is in value investing. I short commodities more often than I short stocks as I prefer to be a stocktimist or stock optimist by nature. I've only recently decided to become a contributor on the site as I'd like to share my research with others to help them with investing.
A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.
I am a Ph.D. level scientist at a major pharmaceutical company. Previously I was an NIH Cancer Postdoctoral fellow at UPENN. Through my extensive research background, I am able to quickly decipher clinical information and act on it. I specialize in analyzing and trading biotech/healthcare stocks both long and short. I maintain a few core positions and trade clinical events based on extensive research to realize large percentage profits. I am open to opportunities in consulting for financial firms or local advisors. Please contact me if you are interested.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
I am a Portuguese independent trader, analyst and algorithmic trading expert, having worked for both sell side (brokerage) and buy side (fund management) institutions.
I've been trading professionally for about 20 years and also launched www.thinkfn.com in 2004. Thinkfn (Think Finance) carries thousands of educational articles on finance and the markets.
I trade futures, stocks from the long and short side, forex and options. I trade both discretionary and fully automated systems (Metatrader, Quantshare and others).
I can be reached at paulo.santosATthinkfn.com or followed on Twitter at twitter.com/ThinkFinance999
Renaissance Capital is an IPO investment advisory firm providing pre-IPO institutional research and management of IPO-focused funds including the Renaissance IPO ETF (NYSE ticker: IPO), the Renaissance International IPO ETF (NYSE ticker: IPOS) and the Global IPO Mutual Fund (ticker: IPOSX). Through Renaissance Capital’s pre-IPO research service, investors get a hard-nosed, independent opinion, in-depth fundamental analysis and customizable financial models on all IPOs. The Firm's clients also gain access to the premier IPO knowledge base with deal calendars, market commentary, fundamental data on over 5,000 past IPOs and more.
At Bio Vantage, our mission is to provide high-quality equity reports focused primarily on biotech and pharmaceutical companies worldwide. In our view, fundamental analysis of biopharmaceutical companies requires expertise in evaluating clinical trial data and drug pipelines, as these events often drive the underlying equity value of such companies going forward. Equally important is the ability to forecast future revenues, earnings growth, and cash flows using financial modeling tools in order to derive an intrinsic value for the company being analyzed. Once a fundamental value is derived, investors can make profits from a variety of trading instruments.
While our expertise largely concerns biotech and pharmaceutical companies, our investment principles are centered on diversification, asset allocation, risk management, and portfolio strategies. Thus, our investments and analyses also cover other sectors, including technology, financials, consumer products, energy, and commodities.
Bio Vantage's analysts have extensive experience in the biomedical field and in drug discovery research. We are lifelong investors. One of the analysts holds the CFA charter designation.
I am a buy side research analyst working for an asset management firm. I aim for a combination of growth and value while investing and recommend the same for others. My sector expertise include financials and healthcare.
In my research, I focus more on cost drivers, revenue drivers and the factors affecting these drivers as financial results are only an output of these drivers.
John M. Mason writes on current monetary and financial events. He is an entrepreneur and a writer. Current projects include a new banking institution, an Internet company, a private equity fund, two depository institutions and a community redevelopment fund. He formerly was on the faculty of the Finance Department, Wharton School, the University of Pennsylvania. Dr. Mason has been President and CEO of two publicly traded financial institutions and the executive vice president and CFO of a third. He has also served as a special assistant to the secretary of the Department of Housing and Urban Development in Washington, D. C. and as a senior economist within the Federal Reserve System. Dr. Mason has served on the boards of venture capital funds and other private equity funds. He has worked with young entrepreneurs, especially within the urban environment, starting or running companies primarily connected with Information Technology. Some of his new ventures are in the sustainable business and impact business space. .
Jeff is a mortgage broker, published author and educator. He is a value/dividend investor who specializes in long term growth. He lives in a beautiful seaside town in BC Canada with his wife and two children.
Caiman Valores is a Colombian based independent investigations and risk management consultancy. It specializes in South American listed companies and conducting regional economic and risk assessments. The principal of Caiman Valores "Matthew Smith" has over a decade of experience in the investment industry. During that time he worked in investment and risk management, investment advisory and corporate strategy. Over the years, he has spent considerable time analyzing investment solutions as well as designing and implementing risk management frameworks for two global banking institutions. Prior to embarking on a career in financial services he built a career in the field of risk management for government security agencies. He has travelled extensively through South America, speaks Spanish and enjoys learning about new cultures and languages as well as travel and adventure. Matthew has a Master of Business Law from the University of Sydney as well as a Master of Arts in International Relations and a Bachelor Degree in Political Science and Economics from the University of New South Wales. Please feel free to contact him regarding investments, writing, or speaking opportunities via email at email@example.com.